IRIS
BODINI, GIORGIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 11.207
AS - Asia 1.463
NA - Nord America 1.135
SA - Sud America 111
AF - Africa 28
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 3
Totale 13.950
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 10.908
US - Stati Uniti d'America 1.060
SG - Singapore 545
CN - Cina 387
VN - Vietnam 261
FR - Francia 112
BD - Bangladesh 100
BR - Brasile 66
HK - Hong Kong 56
DE - Germania 41
CA - Canada 39
FI - Finlandia 39
GB - Regno Unito 37
AR - Argentina 23
MX - Messico 22
ID - Indonesia 20
JP - Giappone 20
NL - Olanda 16
IN - India 15
IQ - Iraq 12
EC - Ecuador 9
PH - Filippine 8
TR - Turchia 7
UA - Ucraina 7
CH - Svizzera 6
KE - Kenya 6
RU - Federazione Russa 6
ZA - Sudafrica 6
JO - Giordania 5
VE - Venezuela 5
ES - Italia 4
IE - Irlanda 4
TN - Tunisia 4
UZ - Uzbekistan 4
AU - Australia 3
AZ - Azerbaigian 3
CL - Cile 3
DZ - Algeria 3
ET - Etiopia 3
JM - Giamaica 3
NP - Nepal 3
PL - Polonia 3
SA - Arabia Saudita 3
XK - ???statistics.table.value.countryCode.XK??? 3
AT - Austria 2
BA - Bosnia-Erzegovina 2
BZ - Belize 2
CR - Costa Rica 2
CZ - Repubblica Ceca 2
IL - Israele 2
KR - Corea 2
LB - Libano 2
LC - Santa Lucia 2
LT - Lituania 2
LV - Lettonia 2
MA - Marocco 2
PE - Perù 2
PK - Pakistan 2
PT - Portogallo 2
PY - Paraguay 2
RO - Romania 2
SE - Svezia 2
TH - Thailandia 2
BB - Barbados 1
BH - Bahrain 1
BY - Bielorussia 1
CO - Colombia 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
EG - Egitto 1
GA - Gabon 1
GG - Guernsey 1
HN - Honduras 1
HR - Croazia 1
HU - Ungheria 1
IR - Iran 1
LY - Libia 1
MD - Moldavia 1
ML - Mali 1
MY - Malesia 1
NI - Nicaragua 1
PA - Panama 1
RS - Serbia 1
SI - Slovenia 1
TW - Taiwan 1
Totale 13.950
Salva come PNG Salva come JPEG
Città #
Genova 5.160
Genoa 3.866
Vado Ligure 928
Rapallo 771
San Jose 269
Singapore 224
Ashburn 182
Lauterbourg 103
Council Bluffs 97
Ho Chi Minh City 81
Beijing 70
New York 59
Hanoi 58
Hong Kong 54
Helsinki 32
Frankfurt am Main 31
Santa Clara 30
Boardman 26
Los Angeles 26
Orem 25
Milan 22
Tokyo 18
Bordighera 17
Mexico City 15
Rome 14
Da Nang 12
Amsterdam 11
Phoenix 11
São Paulo 11
Montreal 10
Chicago 9
Dallas 9
Poplar 9
Tianjin 9
Atlanta 7
Buffalo 7
Haiphong 7
Lappeenranta 7
Toronto 7
Baghdad 6
Bologna 6
London 6
Mumbai 6
Naples 6
Ninh Bình 6
Zurich 6
Amman 5
Cardiff 5
City of London 5
Manchester 5
Memphis 5
Nairobi 5
Bắc Ninh 4
Can Tho 4
Columbus 4
Denver 4
Dublin 4
Guangzhou 4
Hải Dương 4
Kyiv 4
Milwaukee 4
Quảng Ngãi 4
Tashkent 4
Addis Ababa 3
Beachwood 3
Biên Hòa 3
Brasília 3
Brescia 3
Buenos Aires 3
Bình Phước 3
Cape Town 3
Charlotte 3
Cleveland 3
La Plata 3
Modena 3
Nha Trang 3
Padua 3
Philadelphia 3
Pristina 3
Quezon City 3
Recife 3
Rio de Janeiro 3
San Francisco 3
Seattle 3
Shanghai 3
Staten Island 3
Warsaw 3
Washington 3
Ancona 2
Ann Arbor 2
Antalya 2
Baku 2
Belize City 2
Berlin 2
Borgosesia 2
Boston 2
Brooklyn 2
Brugherio 2
Bắc Giang 2
Cachoeira do Sul 2
Totale 12.519
Salva come PNG Salva come JPEG
Nome #
Proton pump inhibitors: use and misuse in the clinical setting 239
Anti-TNF therapy is able to stabilize bowel damage progression in patients with Crohn's disease. A study performed using the Lémann Index 206
Advancements in the use of manometry and impedance testing for esophageal functional disorders 206
Not All Patients With Non-erosive Reflux Disease Share Psychological Distress as Main Mechanism of Disease. 201
Pathophysiology, diagnosis, and pharmacological treatment of gastro-esophageal reflux disease 200
A safety review of proton pump inhibitors to treat acid-related digestive diseases 199
A review of pharmacotherapy for treating gastroesophageal reflux disease (GERD) 194
Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. 193
Comparison of Two Different Techniques to Assess Adalimumab Trough Levels in Patients with Crohn's Disease. 193
High anti-TNF alfa drugs trough levels are not associated with the occurrence of adverse events in patients with inflammatory bowel disease 187
A Closer Look at Factors Associated With Bleeding in Cirrhotic Patients 178
A Nodule, is a Nodule, is a Nodule: May Alpha-fetoprotein Make the Difference? 167
Vonoprazan for treatment of gastroesophageal reflux: pharmacodynamic and pharmacokinetic considerations 167
Impact of evidence-based medicine on treatment of patients with unresectable hepatocellular carcinoma 166
Adalimumab trough serum levels and anti-adalimumab antibodies in the long-term clinical outcome of patients with Crohn’s disease. 166
Anti-TNF Antibodies For Prevention of Crohn's Disease Recurrence After Surgery: More Than An Hope. 166
Reduction in TIMP-2 serum levels predicts remission of inflammatory bowel diseases 166
Adalimumab trough levels and response to biological treatment in patients with Inflammatory Bowel Disease: a useful cut-off In clinical practice. 164
Antimicrobial treatment with the fixed-dose antibiotic combination RHB-104 for Mycobacterium avium subspecies paratuberculosis in Crohn’s disease: pharmacological and clinical implications 161
Low serum trough levels are associated with post-surgical recurrence in Crohn's disease patients undergoing prophylaxis with adalimumab. 159
Bleeding after paracentesis in patients with decompensated cirrhosis and acute kidney injury: the perfect storm 159
Active pharmacovigilance program in patients affected by psoriasis and inflammatory bowel diseases
 159
Harmonising proton pump inhibitors treatment in the specialist setting following the SIGE recommendations 158
Improvement in hepatitis C virus patients with advanced, compensated liver disease after sustained virological response to direct acting antivirals 158
Gadolinium accumulation after contrast-enhanced magnetic resonance imaging: Which implications in patients with Crohn's disease? 157
The role of small intestinal bacterial overgrowth in cystic fibrosis: a randomized case-controlled clinical trial with rifaximin 157
Letter: Biologics are effective in neutralising the detrimental effect of smoking on the natural course of Crohn's disease 155
Infliximab trough levels and persistent vs transient antibodies measured early after induction predict long-term clinical remission in patients with inflammatory bowel disease 155
Low Fibrinogen Levels Are Associated with Bleeding After Varices Ligation in Thrombocytopenic Cirrhotic Patients 155
Optimal management of constipation associated with irritable bowel syndrome. 154
The appropriate use of proton-pump inhibitors 154
Epidemiology and natural history of gastroesophageal reflux disease 149
A randomized, 6-wk trial of a low FODMAP diet in patients with inflammatory bowel disease 149
The natural history of gastro-esophageal reflux disease: A comprehensive review 147
Comparison of the Safety and Efficacy of Ustekinumab and Vedolizumab in Patients with Crohn’s Disease: A Systematic Review and Meta-Analysis of Propensity Score Matched Cohort Studies 144
Tryciclic Antidepressants in Refractory GERD: Poorly Effective Drugs or Wrong Patients? 139
Corticosteroid Treatment at Diagnosis: An Analysis of Relapses, Disease Extension, and Colectomy Rate in Ulcerative Colitis 139
Course of oesophageal varices and performance of non-invasive predictors following Hepatitis C Virus clearance in compensated advanced chronic liver disease 139
Characteristics of reflux episodes and symptom association in patients with erosive esophagitis and nonerosive reflux disease: study using combined impedance-pH off therapy. 135
Prevention of Crohn's disease recurrence after surgery: on the road to recovery. 135
The placebo effect is a relevant factor in evaluating effectiveness of therapies in functional gastrointestinal disorders. 134
Functional Heartburn Overlaps With Irritable Bowel Syndrome More Often than GERD. 134
Gastrointestinal involvement in systemic sclerosis 134
Concerns related to COVID-19 pandemic among patients with Inflammatory Bowel Disease, and its influence on patients management 134
Appropriateness of proton pump inhibitors treatment in clinical practice: Prospective evaluation in outpatients and perspective assessment of drug optimisation 134
Regression of Fibrosis After DAAs Treatment of Patients with HCV Cirrhosis: Transposability to Non-Decompensated Patients 133
Patient and physician views on the quality of care for inflammatory bowel disease after one-year follow-up: Results from SOLUTION-2, a prospective IG-IBD study 130
Novel Prognostic Biomarkers of Mucosal Healing in Ulcerative Colitis Patients Treated With Anti-TNF: Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio 128
Esophagogastric junction contractility for clinical assessment in patients with GERD: a real added value? 126
Translation and initial validation of the Medication Adherence Report Scale (MARS) in Italian patients with Crohn's Disease 126
Esophageal motility abnormalities in gastroesophageal reflux disease 125
Esophageal testing: What we have so far 124
Association between esophageal motor disorders and pulmonary involvement in patients affected by systemic sclerosis: a retrospective study 123
Positive glucose breath testing is more prevalent in patients with IBS-like symptoms compared with controls of similar age and gender distribution. 122
Letter: faecal volatile organic metabolites, promising biomarkers in inflammatory bowel disease. 121
Reproducibility and transportability of the absence of incremental infectious adverse events in patients with higher anti-TNF drug levels 121
Eradication of hepatitis C virus infection disclosing a previously hidden, underlying autoimmune hepatitis: Autoimmune hepatitis and HCV 121
M01822 Diagnostic accuracy and Inter/Intra-observer Agreement between endoscopists with different expertise, before and after a short training, for the detection of gastric intestinal metaplasia by means of narrow band imaging with magnifying endoscopy 119
Applicability of Parameters for the Non-Invasive Diagnosis of Esophageal Varices Needing Treatment to Cured HCV Patients 119
NASH-related and cryptogenic cirrhosis similarities extend beyond cirrhosis 116
Vonoprazan Fumarate for the Treatment of Gastric Ulcers: A Short Review on Emerging Data 115
DEVELOPMENT AND VALIDATION OF A TEST TO MONITOR ENDOSCOPIC ACTIVITY IN PATIENTS WITH CROHN'S DISEASE BASED ON SERUM LEVELS OF PROTEINS 115
High-resolution manometry is superior to endoscopy and radiology in assessing and grading sliding hiatal hernia: A comparison with surgical in vivo evaluation 115
Mediterranean Diet and NAFLD: What We Know and Questions That Still Need to Be Answered 114
Impedance-detected symptom association and number of reflux episodes as pre-treatment parameters that predict outcomes of gastroesophageal reflux disease patients 112
Vegetal and animal food proteins have a different impact in the first postprandial hour of impedance-pH analysis in patients with heartburn 111
Vonoprazan fumarate for the management of acid-related diseases 110
Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study 109
Treatment of early stage chronic hepatitis C virus infection 107
Esophageal motor disorders across ages: A retrospective multicentric analysis 106
Letter: Biological therapies are effective for prevention of post-operative Crohn's disease recurrence 106
Granulocytes and monocytes apheresis induces upregulation of TGFβ1 in patients with active ulcerative colitis: A possible involvement of soluble HLA-I 106
Institution of an interdisciplinary IBD centre is associated with improved healthcare utilisation 105
Response to COVID-19 Vaccination in Patients with Inflammatory Bowel Disease on Biological Treatment 105
Elevated adherence to vaccination against SARS-CoV-2 among patients with Inflammatory Bowel Disease 101
Adalimumab Biosimilar GP2017 versus Adalimumab Originator in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study 99
The Lyon Consensus: Does it differ from the previous ones? 99
Hepatocellular Carcinoma Intermediate Stage Subclassification Systems: One, None, and One Hundred Thousand 98
Autoimmune chronic atrophic gastritis: association between chronic proton pump inhibitors use and more severe atrophy and gastric intestinal metaplasia 95
Therapeutic drug monitoring in Crohn's disease patients treated with anti-TNF: a comparison of two techniques 95
An Objective Comparison of Vedolizumab and Ustekinumab Effectiveness in Crohn's Disease Patients' Failure to TNF-Alpha Inhibitors 94
Prospective evaluation on the prevalence of serrated adenoma during a two-year period in an italian endoscopy centre 94
Intra- and interobserver Agreement between endoscopists and pathologists for detection of gastric intestinal metaplasia by means of narrow band imaging with magnifying endoscopy 91
Letter: vedolizumab or a second anti-TNF-no difference in efficacy for primary biologic failures with IBD 91
A propensity score-weighted comparison between adalimumab originator and its biosimilars, ABP501 and SB5, in inflammatory bowel disease: a multicenter Italian study 90
Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective? 90
Effect of hiatal hernia and esophagogastric junction morphology on esophageal motility: Evidence from high‐resolution manometry studies 89
Prevalence of Lactose Intolerance in Patients with Hashimoto Thyroiditis and Impact on LT4 Replacement Dose 87
Prevention of postoperative recurrence of Crohn's disease by Adalimumab: a case series. 87
Applying Lyon consensus criteria in the work‐up of patients with extra‐oesophageal symptoms – A multicentre retrospective study 85
Albumin-bilirubin score in non-malignant liver diseases should be properly validated 85
Are Small Molecules Effective in Treating Inflammatory Pouch Disorders Following Ileal Pouch-Anal Anastomosis for Ulcerative Colitis? Here Is Where We Stand 84
Clopidogrel-Induced Eosinophilic Colitis 82
Food Intolerances, Food Allergies and IBS: Lights and Shadows 80
The crohn's disease exclusion diet in adults with mild-to-moderate crohn’s disease activity: A real-world open-label randomized controlled trial 79
Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator 78
Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care 75
Risk factors for bleeding following oesophageal band ligation: Providing further evidence to ameliorate clinical practice 75
Nuts and Non-Alcoholic Fatty Liver Disease: Are Nuts Safe for Patients with Fatty Liver Disease? 75
Diagnostic delay in achalasia 74
Totale 13.007
Salva come PNG Salva come JPEG
Categoria #
all - tutte 49.619
article - articoli 49.619
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 99.238
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202183 0 0 0 0 0 0 0 0 0 0 0 83
2021/20221.033 72 34 53 83 35 114 38 238 79 117 51 119
2022/2023963 111 100 14 64 155 118 7 84 166 7 121 16
2023/2024804 28 80 12 106 72 144 64 29 31 35 73 130
2024/20252.427 106 145 116 132 302 269 177 433 104 92 252 299
2025/20264.735 511 211 449 435 538 355 633 219 398 513 306 167
Totale 14.403